公司将依托此契机，通过创新合作模式进一步加强全球合作网络，实现公司技术平台科学与商业价值的 最大化。订立该等协议可通过与经验丰富的投资机构共建专注于HBM4003开发的全球生物技术公司， 加速HBM4003在大中华区以外地区的全球开发和商业化。此合作模式不仅能实现长期价值创造，亦使 公司能够深度参与并推动该资产的全球开发进程。 智通财经APP讯，和铂医药-B(02142)发布公告，公司已与Solstice Oncology(一家由多个大型风险投资机 构创立的临床阶段生物技术公司)订立独家授权协议及股权合作协议(该等协议)，据此，公司同意向 Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。 根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价，包括：5000万美元的首付款， 500万美元的近期付款，及向公司发行及配发于Solstice Oncology的超过5000万美元的股权。此外，公司 亦有资格视乎若干未来事件的达成情况，获得最高约11亿美元的额外开发、监管及商业里程碑付款，以 及基于HBM4003在大中华区以外地区净销售额的分 ...

【文/观察者网 齐倩】 欧盟提出的"地平线欧洲"计划 去年12月，欧盟宣布，自2026年起，中国研究人员被排除"地平线欧洲"合作计划之外。 2月21日，香港《南华早报》报道指出，有美国学者认为，随着中国科技迅速发展，欧盟采用了美国 的"小院高墙"逻辑，标志着中欧在科技领域从伙伴关系转向战略竞争。多名中国专家表示，此禁令对中 国研究影响有限，反而可能使欧洲更加孤立。 据介绍，"地平线欧洲"是欧盟的旗舰研究与创新计划，可追溯至1980年代，已吸引来自100多个国家的 申请者。在上一个资助周期（2014至2020年，约800亿欧元）中，美国和中国是非欧盟参与者中的前两 名。人工智能和量子技术是该计划的优先领域。 近年来，中国已成为人工智能研究的最大产出国，并在量子技术领域与美国争夺主导地位。 在此背景下，欧盟去年12月发布新规，专门用五页篇幅描述针对中国限制措施。 根据新规，欧盟以所谓"研究安全和潜在军事用途"为由，禁止中国境内机构申请其930亿欧元的"地平线 欧洲"资助计划中的"关键领域"。从2026年起生效，该禁令涵盖人工智能、量子技术、半导体和生物技 术等领域。在这些领域申请的非中国研究人员还必须证明合作伙伴 ...

经济观察网 近期药捷安康-B（02617.HK）股价呈现波动下行态势。根据内部数据库，在近一周有交易 的日子中，2月16日收盘价为67.80港元，单日跌幅1.38%；2月20日收盘价为66.60港元，单日跌幅 1.77%。从2月16日至20日，区间跌幅为3.13%，振幅达7.13%，成交相对清淡，换手率较低。资金流向 方面，2月20日总净流入492.68万元，但主力资金净流入为0，散户资金活跃。同期，所属生物技术板块 上涨1.64%，但个股表现与板块走势分化。 以上内容基于公开资料整理，不构成投资建议。 ...

经济观察网 基于截至2026年2月的最新公开信息，宜明昂科-B（股票代码：01541.HK）有以下值得关注 的事件进展，主要涉及核心产品研发、监管申请及合作动态。以下内容均来自公司公告及媒体报道，按 时间顺序和重要性梳理。 产品研发进展 III期临床试验中期分析：公司核心产品IMM01（替达派西普）用于慢性粒-单核细胞白血病（CMML） 一线治疗的III期临床试验，已于2025年12月31日完成104例患者招募，预计在2026年3月底前完成中期分 析所需的132例患者招募。中期分析数据将用于评估完全缓解率（CR率），为后续申请奠定基础。 合作调整与资产回收：2026年1月，公司终止与Instil Bio子公司Axion Bio的许可协议，收回IMM2510 （PD-L1xVEGF双抗）和IMM27M（CTLA-4抗体）的全球权利，并保留已收到的3500万美元付款。创 始人田文志表示，公司正与多家跨国药企接触，计划在2026年寻求新的合作伙伴以推进全球化开发。 公司状况 公司治理事件：2026年2月10日，公司向创始人田文志提供了一笔本金为1372.47万元人民币的贷款，公 告称此举基于公司财务状况良好，且不会 ...

Core Insights - McKinsey's report identifies 18 industry sectors likely to reshape the global business landscape, predicting revenues of $29 trillion to $48 trillion by 2040, contributing 18-34% to global GDP growth [2] E-commerce - By 2040, e-commerce's share of global retail revenue is expected to rise to 27%-38%, up from approximately 20% currently [3] - Growth drivers include market expansion in developing countries and new product categories in developed nations, such as healthcare and emotionally valuable products [4] - Significant investments are anticipated in customer acquisition and last-mile delivery across e-commerce platforms [5] Electric Vehicles - Electric vehicles (EVs) are projected to exceed 50% of global passenger car sales by 2040 [6] - Breakthroughs in battery technology and smart algorithms will significantly influence this sector, prompting increased R&D investments from both EV manufacturers and traditional automakers [7] Cloud Services - The demand for higher storage and computing capabilities is driven by a more interconnected world and the need for AI products requiring substantial computational power [9] - The cloud services industry experienced a 17% compound annual growth rate (CAGR) from 2005 to 2020, with similar growth expected in the coming decades [10] Semiconductors - The semiconductor industry is essential for the digital world, with demand from computing, data storage, automotive, communication, and industrial electronics driving growth [11] - A sustained CAGR of 6%-8% is forecasted for the semiconductor sector over the next decade [11] AI Software Services - The rapid development of AI has led to its classification as a distinct sector, with increasing usage of AI assistants [12] - Companies in the AI space are engaged in a competitive race to develop advanced foundational models and applications [13] Digital Advertising - Digital advertising, through search, social media, and media services, is expanding in value as internet usage among the middle class increases [14] - Continuous algorithm improvements enhance platforms' abilities to target customers and track advertising costs, although competition for user attention necessitates increased investment in engaging content [15] Streaming Video - Investment in customer acquisition and content production is rising, prompting streaming platforms to seek new revenue models [17] - Developing countries may provide incremental growth in subscription and advertising revenue for streaming services, with projections indicating over 1 billion households subscribing to long-form video services by 2040 [18] Shared Autonomous Vehicles - The advent of autonomous driving technology may reduce the necessity for personal vehicle ownership [19] - By 2040, shared autonomous vehicles could account for 25%-51% of shared mobility revenue [20] Space Economy - The world is on the brink of entering a space economy era, with advancements in reusable rocket technology transforming the aerospace industry [21][22] Cybersecurity - Cybercrime caused approximately $950 billion in direct economic losses in 2020, with indirect losses potentially reaching $4-6 trillion [24] - Increasing awareness of cybersecurity has led companies to enhance their investments in this area [25] Batteries - Significant advancements in battery technology have tripled energy density over the past few decades [26] - The global energy transition is driving demand for batteries, particularly in electric vehicles, energy storage, and consumer electronics, with EVs expected to represent over 80% of the battery market by 2040 [28] Video Games - By 2030, an estimated 40% of the global population may become video game players [30] - New gaming models, such as mobile and cloud gaming, are accelerating market growth, with free-to-play games generating substantial revenue [32] Robotics - The integration of AI with robotics is creating significant expectations for humanoid robots, which are seen as potential "ultimate intelligent agents" [33] Industrial and Consumer Biotechnology - Breakthroughs in gene editing and other technologies are accelerating the application of biotechnology in agriculture, alternative proteins, consumer products, and bio-materials [37] Modular Construction - Modular construction methods, which involve prefabricating building components for on-site assembly, can significantly enhance construction efficiency [38] Nuclear Fission Power - The development of safer, smaller modular reactors presents opportunities to supplement renewable energy sources [39] Air Traffic - Electric vertical takeoff and landing vehicles and delivery drones are expected to drive significant technological changes in air traffic [41] Obesity Treatment Drugs - The prevalence of obesity is projected to rise from 15% in 2020 to 24% by 2035, indicating a potential market for effective weight loss products [43]

Stock Performance - On February 16, 2026, the closing price of Baiaosaitu-B (02315.HK) was HKD 50.95, reflecting a daily decline of 4.77% with a trading volume of 18,000 shares and a turnover of approximately HKD 924,500, indicating a low turnover rate of only 0.02% [1] - The stock price fell below the 5-day moving average of HKD 52.03, while the upper Bollinger Band at HKD 54.957 exerted pressure on the stock price, suggesting a weakening short-term upward momentum [1] - In contrast, the Hang Seng Index rose by 0.52%, while the biotechnology sector, to which the company belongs, experienced a slight decline of 0.02%, indicating a divergence between the stock's performance and the sector's trend [1] Capital Movements - Vico (Hong Kong) Trading Co., Ltd. increased its holdings by 786,000 H-shares at an average price of HKD 27.2784 per share on February 2, raising its ownership from 7.31% to 8.02%, with this change disclosed on February 16 [2] - The purchase price was significantly lower than the closing price of HKD 50.95 on February 16, which may raise concerns among investors regarding short-term valuation pressure [2]

Summary of Allogene Therapeutics Conference Call Company Overview - **Company**: Allogene Therapeutics (NasdaqGS:ALLO) - **Event**: 2026 Conference at Citi's Virtual Oncology Leadership Summit - **Key Speaker**: Zach Roberts, Chief Medical Officer Core Industry and Product Insights - **Product**: Cema-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 - **Study**: ALPHA-3 study, focusing on newly diagnosed large B-cell lymphoma patients - **Study Design**: Patients achieving remission after standard frontline treatment undergo a minimal residual disease (MRD) test. MRD positive patients are randomized to either observation or treatment with cema-cel [3][4][5][6] Key Points and Arguments - **Efficacy and Safety**: Cema-cel has shown comparable efficacy to autologous CAR T products with improved safety profiles, including lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [4][5] - **MRD Testing**: The ALPHA-3 study utilizes a highly sensitive PCR-based MRD test to identify patients at high risk of relapse. The study aims to determine if treating MRD positive patients with cema-cel can improve long-term outcomes [6][8] - **Expected Outcomes**: A 25%-30% absolute improvement in MRD clearance is anticipated between the treatment and observation arms. Historical data suggests a baseline MRD clearance rate of around 20% in the observation arm [11][12][14] - **Clinical Context**: The study is positioned as a frontline treatment, with MRD status being a new eligibility criterion for treatment decisions. This approach is innovative compared to traditional methods that do not incorporate MRD testing [15][16] Additional Important Insights - **Patient Journey**: The study allows for flexibility in treatment decisions based on individual patient circumstances, with a significant proportion of patients being treated in community settings [36][37] - **Enrollment Progress**: Initial challenges in patient enrollment have been addressed, and the study is now seeing routine MRD testing for eligible patients [40][41] - **Commercial Strategy**: Allogene anticipates a significant market opportunity for cema-cel, especially as MRD testing becomes more prevalent. The acquisition of Foresight Diagnostics by Natera is expected to enhance MRD testing capabilities [35][58] - **Future Expectations**: The upcoming futility analysis in April is viewed as a critical milestone that could de-risk the overall study and potentially revolutionize treatment practices for lymphoma patients [70][72] Conclusion - Allogene Therapeutics is poised to make significant advancements in the treatment of large B-cell lymphoma through the ALPHA-3 study and the use of cema-cel. The integration of MRD testing into treatment protocols represents a paradigm shift in patient management and could lead to improved outcomes for patients at risk of relapse [72]

Financial Data and Key Metrics Changes - The company reported Q4 2025 net revenue of $107.1 million, marking a growth of almost 10% compared to the previous quarter and approximately 18% year-over-year [25][26] - Year-to-date net revenue for VYJUVEK reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [25] - Gross margin for Q4 was 94%, down from 96% in Q3 2025 and 95% in Q4 2024, attributed to increased sales outside the U.S. which carry higher costs [26] Business Line Data and Key Metrics Changes - VYJUVEK continues to show strong performance with total net revenue since launch exceeding $730 million [6] - The company has signed distributor agreements covering more than 20 countries, aiming to expand to over 40 countries in 2026 [4] - The U.S. market saw over 660 reimbursement approvals, with more than 500 unique prescribers since launch [9] Market Data and Key Metrics Changes - In Europe, over 90 DEB patients have been prescribed VYJUVEK across Germany, France, and Japan, with sustained prescription growth in Germany [11][12] - The launch in Japan has been successful, with a unique distribution model enabling home delivery [13] - Pricing negotiations are ongoing in Germany and France, with expectations for agreements in the second half of 2026 and 2027 respectively [12][14] Company Strategy and Development Direction - The company is focused on expanding global access for VYJUVEK while advancing a disciplined pipeline of gene therapies [5] - Plans to initiate two additional registrational programs in cystic fibrosis and Hailey-Hailey disease later this year [5] - The company aims to build a durable commercial gene therapy business with strong capital allocation and operational improvements [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for VYJUVEK, particularly in international markets, which are expected to drive revenue growth in 2026 [30] - The company is aware of the evolving utilization patterns among U.S. patients, shifting towards more intermittent treatment cycles [31] - Management remains optimistic about the potential of their pipeline programs, especially with recent FDA designations that could accelerate development timelines [33] Other Important Information - The company ended the year with $955.9 million in cash and investments, positioning it well for future commercial launches and pipeline milestones [29] - R&D expenses for Q4 were $14.8 million, while SG&A expenses were $41.4 million, reflecting increased headcount and marketing costs [27] Q&A Session Summary Question: Visibility into Q1 and 2026 revenue contribution from U.S. vs. ex-U.S. - Management indicated that while growth will predominantly come from ex-U.S. markets, demand in the U.S. is also accelerating, with expectations to break out revenue in Q1 [36] Question: Data supporting modified dosing regimens for ocular and NK - Management confirmed that the changes were based on patient feedback and the need for home administration, ensuring compliance and convenience [40] Question: Compliance rates in EU and Japan - Compliance in Europe has been consistent with the U.S., while Japan's two-week prescription requirement may affect long-term compliance [46] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in the second half of 2026, while negotiations in France may extend into 2027 [54] Question: Differentiating factors for dosing schedules in ocular studies - The decision for different dosing regimens was based on patient convenience and feedback, with no changes to the dose volume [70]

机构评级方面，2026年2月有15家机构发布观点，其中80%给予买入或增持评级，目标均价54.54美元， 较当前价存在显著溢价。盈利预测显示公司仍处于研发投入期，2025年第四季度预测每股收益为-1.009 美元，但长期关注点集中于Barzol等管线的临床进展。 以上内容基于公开资料整理，不构成投资建议。 近7天（2026年2月9日至13日）股价呈现震荡下行趋势，区间累计跌幅3.20%，振幅达11.49%。2月9日 单日上涨4.42%至24.81美元，但2月12日下跌4.19%，2月13日续跌2.42%至23.00美元，成交额在2月13日 放大至2731万美元，换手率1.79%，资金活跃度短期上升。同期所属生物技术板块上涨1.32%，但个股 表现偏离板块，大盘纳斯达克指数下跌0.22%。 机构观点 经济观察网 塞德斯医疗于2026年2月12日公布2026年关键研发规划，Barzol药物针对慢性自发性荨麻疹 （CSU）的III期临床试验预计于2026年7月完成患者入组，该事件被管理层列为年度重点。2月14日，公 司进一步明确战略焦点，计划在2026年公布结节性痒疹和特应性皮炎的II期数据，并推进双特异性平台 C ...

Core Insights - McKinsey's report identifies 18 industry sectors likely to reshape the global business landscape, predicting revenues of $29 trillion to $48 trillion by 2040, contributing 18-34% to global GDP growth [2]. E-commerce - By 2040, e-commerce's share of global retail revenue is expected to rise to 27%-38%, up from approximately 20% currently [3]. - Growth drivers include market expansion in developing countries and new product categories in developed nations, such as healthcare and emotionally valuable products [4]. - Significant investments are anticipated in customer acquisition and last-mile delivery across e-commerce platforms [5]. Electric Vehicles - Electric vehicles (EVs) are projected to exceed 50% of global passenger car sales by 2040 [6]. - Breakthroughs in battery technology and smart algorithms will significantly influence this sector, prompting increased R&D investments from both EV manufacturers and traditional automakers [7]. Cloud Services - The demand for higher storage and computing capabilities is driven by a more interconnected world and the need for AI products requiring substantial computing power [9]. - The cloud services industry experienced a compound annual growth rate (CAGR) of 17% from 2005 to 2020, with similar growth expected in the coming decades [10]. Semiconductors - The semiconductor industry is essential for the digital world, with demand from computing, data storage, automotive, communication, and industrial electronics driving growth [11]. - A sustained CAGR of 6%-8% is forecasted for the semiconductor sector over the next decade [11]. AI Software Services - The rapid development of AI has led to its classification as a distinct sector, with increasing usage of AI assistants [12]. - Companies in the AI space are engaged in a competitive race to develop advanced foundational models and applications [13]. Digital Advertising - Digital advertising, through search, social media, and media services, is expanding in value as internet usage among the middle class increases [14]. - Continuous algorithm improvements enhance platforms' abilities to target customers and track advertising costs, although competition for user attention necessitates increased investment in engaging content [15]. Streaming Video - Investment in customer acquisition and content production is rising, prompting streaming platforms to seek new revenue models [17]. - Developing countries may provide incremental growth in subscription and advertising revenue for streaming services, with projections indicating over 1 billion households subscribing to long-form video services by 2040 [18]. Shared Autonomous Vehicles - The advent of autonomous driving technology may reduce the necessity for personal vehicle ownership [19]. - By 2040, shared autonomous vehicles could account for 25%-51% of shared mobility revenue [20]. Space Economy - The world is on the brink of entering a space economy era, with advancements in reusable rocket technology transforming the aerospace industry [21][22]. Cybersecurity - Cybercrime caused direct economic losses of approximately $950 billion in 2020, with indirect losses potentially reaching $4-6 trillion [24]. - Increasing awareness of cybersecurity has led companies to enhance their investments in this area [25]. Batteries - Significant advancements in battery technology have tripled energy density over the past few decades [26]. - The global energy transition is driving demand for batteries, particularly in electric vehicles, energy storage, and consumer electronics, with EVs expected to represent over 80% of the battery market by 2040 [28]. Video Games - By 2030, an estimated 40% of the global population may become video game players [30]. - New gaming models, such as mobile and cloud gaming, are accelerating market growth, with free-to-play games generating substantial revenue [32]. Robotics - The integration of AI with robotics is creating significant expectations for humanoid robots, which are anticipated to become "ultimate intelligent agents" [33]. Industrial and Consumer Biotechnology - Breakthroughs in gene editing and other technologies are expected to accelerate the application of biotechnology in agriculture, alternative proteins, consumer products, and bio-materials [37]. Modular Construction - Modular construction methods, which involve prefabricating building components for on-site assembly, can significantly enhance construction efficiency [38]. Nuclear Fission Power - The development of safer, smaller modular reactors may complement renewable energy sources, with commitments from over 20 countries to double nuclear energy production by 2050 [40]. Air Traffic - Electric vertical takeoff and landing vehicles and delivery drones represent significant technological changes in air traffic [41]. Obesity Treatment Drugs - The prevalence of obesity is projected to rise from 15% in 2020 to 24% by 2035, indicating a potential market for effective weight loss products [43].